Novartis arthritis drug fails to benefit COVID-19 patients

Novartis said it will submit the complete outcomes to a peer-reviewed journal soon..

The Novartis arthritis drug Ilaris didnt enhance survival rates for COVID-19 patients or affect their death rate, the drugmaker said Nov. 6..

More articles on drug store: CVS CEO to step down, hand reins to Aetna chiefAllogene reports client death connected to its CAR-T drugSandoz, Civica Rx ship initially drug to United States healthcare facilities.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.

” Theres still an immediate requirement for effective ways to fight COVID-19, and we will continue to use our best scientific minds in assistance of the global pandemic reaction,” Dr. Tsai stated..

Check out the full press release here..

Novartis CMO John Tsai, MD, said that while the drug didnt reveal the benefit the company was hoping for, it assisted to improve scientific understanding of COVID-19 and the role of comparable drugs..

The trial results do not affect any other trials for Ilaris, including those evaluating it for non-small cell lung cancer..

Maia Anderson –
Friday, November 6th, 2020
Print|Email.